13D Filing: Sarissa Capital Management and Novelion Therapeutics Inc. (NVLN)

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13D

 

Under the Securities Exchange Act of 1934

(Amendment No. 3)*

Novelion
Therapeutics Inc.

(Name of Issuer)

 

Common Stock, without par value

(Title of Class of Securities)

 

67001K202

(CUSIP Number)

 

Mark DiPaolo

General Counsel

Sarissa Capital Management LP

660 Steamboat Road

Greenwich, CT 06830

203-302-2330

With a copy to:

Todd E. Mason

Thompson Hine
LLP

335 Madison
Avenue

12^th Floor

New York, New York 10017-4611

(212)
344-5680

(Name, Address and Telephone Number of Person
Authorized to Receive Notices and Communications)

 

 

March 15, 2018

(Date of Event which Requires Filing of this Statement)

 

 

If
the filing person has previously filed a statement on Schedule 13G to report the acquisition which is the subject of this
Schedule 13D, and is filing this schedule because of Rule 13d-1(e), 13d-1(f) or 13d-1(g), check the following box. ¨

Note: Schedules
filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7 for
other parties to whom copies are to be sent.

*The remainder of this cover page shall be filled out for a
reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment
containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder
of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of
1934 or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act
(however, see the Notes).